Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry

Autor: Margalida, Calafat, Míriam, Mañosa, Francisco, Mesonero, Jordi, Guardiola, Miguel, Mínguez, Pilar, Nos, Isabel, Vera, Carlos, Taxonera, Eva, Iglesias, Elena, Ricart, Javier P, Gisbert, Xavier, Calvet, Santiago, García-López, David, Monfort, José Lázaro, Pérez Calle, Sabino, Riestra, Fernando, Gomollón, Esther, Garcia-Planella, Fernando, Bermejo, Vicent, Hernández, María Dolores, Martín-Arranz, Ana, Gutiérrez, Paola, Torres, Fiorella, Cañete, Eugeni, Domènech, Zabana, Yamile
Rok vydání: 2020
Předmět:
Adult
Male
medicine.medical_specialty
Drug-Related Side Effects and Adverse Reactions
Concordance
Inflammatory bowel disease
elderly
03 medical and health sciences
0302 clinical medicine
inflammatory bowel disease
Internal medicine
Azathioprine
medicine
Humans
030212 general & internal medicine
Practice Patterns
Physicians'

Adverse effect
Thiopurine
elderly
inflammatory bowel disease

Aged
Thiopurine methyltransferase
biology
Thiopurine
business.industry
Drug Substitution
Mercaptopurine
Gastroenterology
Age Factors
General Medicine
Odds ratio
Drug Tolerance
medicine.disease
Inflammatory Bowel Diseases
Confidence interval
digestive system diseases
Clinical Practice
Spain
biology.protein
Acute pancreatitis
030211 gastroenterology & hepatology
Female
Risk Adjustment
Drug Monitoring
business
Immunosuppressive Agents
Zdroj: Journal of Crohns & Colitis
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Journal of Crohn's & colitis
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
JOURNAL OF CROHNS & COLITIS
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-IIB SANT PAU: Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
ISSN: 1873-9946
1876-4479
Popis: Background and Aims Although commonly used in inflammatory bowel disease [IBD], thiopurines frequently cause intolerance, and switching to a second thiopurine has only been reported in some small series. Ours aims in this study were to evaluate the safety of switching to a second thiopurine in a large cohort, and to assess the impact of age on tolerance. Methods Adult IBD patients from the ENEIDA registry, who were switched to a second thiopurine due to adverse events [excluding malignancies and infections], were identified. At the beginning of thiopurine treatment, patients were divided by age into two groups: 18–50 and over 60 years of age. The rate and concordance of adverse events between the first and second thiopurines, treatment intolerance, and persistence with the second thiopurine were evaluated. Results A total of 1278 patients [13% over 60 years of age] were switched to a second thiopurine. At 12 months, the cumulative probability of switch intolerance was 43%, and persistence with treatment was 49%. Independent risk factors of switch intolerance were age over 60 years (odds ratio [OR] 1.49; 95% confidence interval [CI] 1.07–2.07; p = 0.017) , previous gastrointestinal toxicity [OR 1.4; 95% CI 1.11–1.78; p = 0.005], previous acute pancreatitis [OR 6.78; 95% CI 2.55–18.05; p Conclusions In a large series in clinical practice, switching to a second thiopurine proved to be a valid strategy. Tight monitoring of elderly IBD patients switching to a second thiopurine because of adverse events is recommended.
Databáze: OpenAIRE